Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 26

1.

Tumor growth fueled by spurious senescence phenotypes.

Mastri M, Ebos JML.

Mol Cell Oncol. 2019 Feb 20;6(2):1575707. doi: 10.1080/23723556.2019.1575707. eCollection 2019.

PMID:
31131302
2.

A Transient Pseudosenescent Secretome Promotes Tumor Growth after Antiangiogenic Therapy Withdrawal.

Mastri M, Tracz A, Lee CR, Dolan M, Attwood K, Christensen JG, Liu S, Ebos JML.

Cell Rep. 2018 Dec 26;25(13):3706-3720.e8. doi: 10.1016/j.celrep.2018.12.017.

3.

Tumor-Independent Host Secretomes Induced By Angiogenesis and Immune-Checkpoint Inhibitors.

Mastri M, Lee CR, Tracz A, Kerbel RS, Dolan M, Shi Y, Ebos JML.

Mol Cancer Ther. 2018 Jul;17(7):1602-1612. doi: 10.1158/1535-7163.MCT-17-1066. Epub 2018 Apr 25.

PMID:
29695634
4.

Sunitinib Stimulates Expression of VEGFC by Tumor Cells and Promotes Lymphangiogenesis in Clear Cell Renal Cell Carcinomas.

Dufies M, Giuliano S, Ambrosetti D, Claren A, Ndiaye PD, Mastri M, Moghrabi W, Cooley LS, Ettaiche M, Chamorey E, Parola J, Vial V, Lupu-Plesu M, Bernhard JC, Ravaud A, Borchiellini D, Ferrero JM, Bikfalvi A, Ebos JM, Khabar KS, Grépin R, Pagès G.

Cancer Res. 2017 Mar 1;77(5):1212-1226. doi: 10.1158/0008-5472.CAN-16-3088. Epub 2017 Jan 13.

5.

Revisiting the Revolution: Examining the Evolving Role of Antiangiogenic Therapy in Cancer

Ebos JM, Quintela-Fandino M.

Curr Drug Targets. 2016;17(15):1706. No abstract available.

PMID:
27109490
6.

The Challenges of Modeling Drug Resistance to Antiangiogenic Therapy.

Mastri M, Rosario S, Tracz A, Frink RE, Brekken RA, Ebos JM.

Curr Drug Targets. 2016;17(15):1747-1754. Review.

7.

Modeling Spontaneous Metastasis following Surgery: An In Vivo-In Silico Approach.

Benzekry S, Tracz A, Mastri M, Corbelli R, Barbolosi D, Ebos JM.

Cancer Res. 2016 Feb 1;76(3):535-47. doi: 10.1158/0008-5472.CAN-15-1389. Epub 2015 Oct 28.

8.

Prodding the Beast: Assessing the Impact of Treatment-Induced Metastasis.

Ebos JM.

Cancer Res. 2015 Sep 1;75(17):3427-35. doi: 10.1158/0008-5472.CAN-15-0308. Epub 2015 Jul 30. Review.

9.

Neoadjuvant antiangiogenic therapy reveals contrasts in primary and metastatic tumor efficacy.

Ebos JM, Mastri M, Lee CR, Tracz A, Hudson JM, Attwood K, Cruz-Munoz WR, Jedeszko C, Burns P, Kerbel RS.

EMBO Mol Med. 2014 Dec;6(12):1561-76. doi: 10.15252/emmm.201403989.

10.

Classical mathematical models for description and prediction of experimental tumor growth.

Benzekry S, Lamont C, Beheshti A, Tracz A, Ebos JM, Hlatky L, Hahnfeldt P.

PLoS Comput Biol. 2014 Aug 28;10(8):e1003800. doi: 10.1371/journal.pcbi.1003800. eCollection 2014 Aug.

11.

Modeling spontaneous metastatic renal cell carcinoma (mRCC) in mice following nephrectomy.

Tracz A, Mastri M, Lee CR, Pili R, Ebos JM.

J Vis Exp. 2014 Apr 29;(86). doi: 10.3791/51485.

12.

Preclinical recapitulation of antiangiogenic drug clinical efficacies using models of early or late stage breast cancer metastatis.

Kerbel RS, Guerin E, Francia G, Xu P, Lee CR, Ebos JM, Man S.

Breast. 2013 Aug;22 Suppl 2:S57-65. doi: 10.1016/j.breast.2013.07.011. Review.

PMID:
24074794
13.

Mind the gap: potential for rebounds during antiangiogenic treatment breaks.

Ebos JM, Pili R.

Clin Cancer Res. 2012 Jul 15;18(14):3719-21. doi: 10.1158/1078-0432.CCR-12-1459. Epub 2012 Jun 7.

14.

Antiangiogenic therapy: impact on invasion, disease progression, and metastasis.

Ebos JM, Kerbel RS.

Nat Rev Clin Oncol. 2011 Mar 1;8(4):210-21. doi: 10.1038/nrclinonc.2011.21. Review. Erratum in: Nat Rev Clin Oncol. 2011;8(4):221. Nat Rev Clin Oncol. 2011 Jun;8(6):316.

15.

Peering into the aftermath: The inhospitable host?

Kerbel RS, Ebos JM.

Nat Med. 2010 Oct;16(10):1084-5. doi: 10.1038/nm1010-1084. No abstract available.

PMID:
20930748
16.

Tumor and host-mediated pathways of resistance and disease progression in response to antiangiogenic therapy.

Ebos JM, Lee CR, Kerbel RS.

Clin Cancer Res. 2009 Aug 15;15(16):5020-5. doi: 10.1158/1078-0432.CCR-09-0095. Epub 2009 Aug 11. Review.

17.

Dose-dependent increases in circulating TGF-alpha and other EGFR ligands act as pharmacodynamic markers for optimal biological dosing of cetuximab and are tumor independent.

Mutsaers AJ, Francia G, Man S, Lee CR, Ebos JM, Wu Y, Witte L, Berry S, Moore M, Kerbel RS.

Clin Cancer Res. 2009 Apr 1;15(7):2397-405. doi: 10.1158/1078-0432.CCR-08-1627. Epub 2009 Mar 10.

18.

Accelerated metastasis after short-term treatment with a potent inhibitor of tumor angiogenesis.

Ebos JM, Lee CR, Cruz-Munoz W, Bjarnason GA, Christensen JG, Kerbel RS.

Cancer Cell. 2009 Mar 3;15(3):232-9. doi: 10.1016/j.ccr.2009.01.021.

19.

Vascular endothelial growth factor-mediated decrease in plasma soluble vascular endothelial growth factor receptor-2 levels as a surrogate biomarker for tumor growth.

Ebos JM, Lee CR, Bogdanovic E, Alami J, Van Slyke P, Francia G, Xu P, Mutsaers AJ, Dumont DJ, Kerbel RS.

Cancer Res. 2008 Jan 15;68(2):521-9. doi: 10.1158/0008-5472.CAN-07-3217.

20.

Multiple circulating proangiogenic factors induced by sunitinib malate are tumor-independent and correlate with antitumor efficacy.

Ebos JM, Lee CR, Christensen JG, Mutsaers AJ, Kerbel RS.

Proc Natl Acad Sci U S A. 2007 Oct 23;104(43):17069-74. Epub 2007 Oct 17.

21.

Cellular and molecular surrogate markers to monitor targeted and non-targeted antiangiogenic drug activity and determine optimal biologic dose.

Shaked Y, Bocci G, Munoz R, Man S, Ebos JM, Hicklin DJ, Bertolini F, D'Amato R, Kerbel RS.

Curr Cancer Drug Targets. 2005 Nov;5(7):551-9. Review.

PMID:
16305351
22.

Down-regulation of DNA mismatch repair proteins in human and murine tumor spheroids: implications for multicellular resistance to alkylating agents.

Francia G, Green SK, Bocci G, Man S, Emmenegger U, Ebos JM, Weinerman A, Shaked Y, Kerbel RS.

Mol Cancer Ther. 2005 Oct;4(10):1484-94.

23.

Increased plasma vascular endothelial growth factor (VEGF) as a surrogate marker for optimal therapeutic dosing of VEGF receptor-2 monoclonal antibodies.

Bocci G, Man S, Green SK, Francia G, Ebos JM, du Manoir JM, Weinerman A, Emmenegger U, Ma L, Thorpe P, Davidoff A, Huber J, Hicklin DJ, Kerbel RS.

Cancer Res. 2004 Sep 15;64(18):6616-25.

24.

A naturally occurring soluble form of vascular endothelial growth factor receptor 2 detected in mouse and human plasma.

Ebos JM, Bocci G, Man S, Thorpe PE, Hicklin DJ, Zhou D, Jia X, Kerbel RS.

Mol Cancer Res. 2004 Jun;2(6):315-26.

25.

Dok-R binds c-Abl and regulates Abl kinase activity and mediates cytoskeletal reorganization.

Master Z, Tran J, Bishnoi A, Chen SH, Ebos JM, Van Slyke P, Kerbel RS, Dumont DJ.

J Biol Chem. 2003 Aug 8;278(32):30170-9. Epub 2003 May 30.

26.

Imatinib mesylate (STI-571) reduces Bcr-Abl-mediated vascular endothelial growth factor secretion in chronic myelogenous leukemia.

Ebos JM, Tran J, Master Z, Dumont D, Melo JV, Buchdunger E, Kerbel RS.

Mol Cancer Res. 2002 Dec;1(2):89-95.

Supplemental Content

Support Center